<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812441999</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812441999</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Movement Disorder in Ataxia-Telangiectasia</article-title>
<subtitle>Treatment With Amantadine Sulfate</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nissenkorn</surname>
<given-names>Andreea</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0883073812441999">1</xref>
<xref ref-type="aff" rid="aff2-0883073812441999">2</xref>
<xref ref-type="corresp" rid="corresp1-0883073812441999"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hassin-Baer</surname>
<given-names>Sharon</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0883073812441999">3</xref>
<xref ref-type="aff" rid="aff4-0883073812441999">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lerman</surname>
<given-names>Sheera F.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff3-0883073812441999">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Levi</surname>
<given-names>Yonit Banet</given-names>
</name>
<degrees>RN</degrees>
<xref ref-type="aff" rid="aff1-0883073812441999">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tzadok</surname>
<given-names>Michal</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073812441999">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ben-Zeev</surname>
<given-names>Bruria</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0883073812441999">2</xref>
<xref ref-type="aff" rid="aff4-0883073812441999">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883073812441999">
<label>1</label>The National A-T Clinic, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel</aff>
<aff id="aff2-0883073812441999">
<label>2</label>Pediatric Neurology Unit, Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Ramat Gan, Israel</aff>
<aff id="aff3-0883073812441999">
<label>3</label>Department of Neurology, Parkinson’s Disease and Movement Disorders Clinic, Sagol Neuroscience Center, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel</aff>
<aff id="aff4-0883073812441999">
<label>4</label>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</aff>
<author-notes>
<corresp id="corresp1-0883073812441999">Andreea Nissenkorn, MD, Pediatric Neurology Unit, Edmond and Lilly Safra Children's Hospital, The Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, 52621, Israel. Email: <email>Andreea.Nissenkorn@sheba.health.gov.il</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>2</issue>
<fpage>155</fpage>
<lpage>160</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>2</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Ataxia-telangiectasia is a cerebellar neurodegenerative disorder presenting with ataxia, chorea, myoclonus, and bradykinesia. Literature on treatment of movement disorders is scarce. We treated 17 children (aged 11.2 ± 3.9 years) for 8 weeks with the dopaminergic and anti-<italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) agent amantadine sulfate 6.3 ± 0.87 mg/kg/d. Ataxia was assessed by using the International Cooperative Ataxia Scale, parkinsonism by the Unified Parkinson Disease Rating Scale, and chorea/myoclonus by the Abnormal Involuntary Movement Scale. Responders were considered those patients who had at least 20% improvement in the summation of the 3 scales. Overall, 76.5% of patients were responders, with a mean 29.3% improvement. Ataxia, involuntary movements, and parkinsonism improved significantly (25.3%, 32.5%, and 29.5%, respectively); (<italic>P</italic> &lt; .001, <italic>t</italic> test). Side effects were mild and transient, and they did not lead to drug discontinuation. Amantadine is a well-tolerated and effective treatment for motor symptoms in ataxia telangiectasia. Assessment of long-term effects and a double-blind study should follow.</p>
</abstract>
<kwd-group>
<kwd>chorea</kwd>
<kwd>bradykinesia</kwd>
<kwd>NMDA antagonists</kwd>
<kwd><italic>N</italic>-methyl-<sc>d</sc>-aspartate</kwd>
<kwd>ataxia-telangiectasia</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Ataxia-telangiectasia is a complex genetic multisystem disorder presenting with a neurodegenerative course, immune deficiency, and cancer predisposition due to mutations in the ATM gene.<sup><xref ref-type="bibr" rid="bibr1-0883073812441999">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073812441999">2</xref></sup> The neurologic picture is mainly known for progressive ataxia, dysmetria, dysarthria, and oculomotor apraxia caused by cerebellar neurodegeneration and atrophy.<sup><xref ref-type="bibr" rid="bibr1-0883073812441999">1</xref><xref ref-type="bibr" rid="bibr2-0883073812441999"/>–<xref ref-type="bibr" rid="bibr3-0883073812441999">3</xref></sup> Although basal ganglia seem uninvolved on neuroimaging, extrapyramidal symptoms (chorea, dystonia, or bradykinesia) may be as disabling.<sup><xref ref-type="bibr" rid="bibr1-0883073812441999">1</xref><xref ref-type="bibr" rid="bibr2-0883073812441999"/>–<xref ref-type="bibr" rid="bibr3-0883073812441999">3</xref></sup> Drooling and fatigue are also major concerns. Ataxia starts around walking age; toward the second decade of life children are usually bound to wheelchairs and rarely survive beyond the 20th birthday. Prognosis is poor because no drug seems to change the disease course. Symptomatic treatment of the motor impairment is likewise lacking documentation, and clinical trials are sparse.<sup><xref ref-type="bibr" rid="bibr4-0883073812441999">4</xref><xref ref-type="bibr" rid="bibr5-0883073812441999"/>–<xref ref-type="bibr" rid="bibr6-0883073812441999">6</xref></sup> Interventional trials are hampered by the lack of universal rating scales for measuring the complex neurologic impairment in ataxia telangiectasia.<sup><xref ref-type="bibr" rid="bibr1-0883073812441999">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073812441999">2</xref>,<xref ref-type="bibr" rid="bibr4-0883073812441999">4</xref>,<xref ref-type="bibr" rid="bibr5-0883073812441999">5</xref></sup></p>
<p>Amantadine is an anti-influenza agent United States Food and Drug Administration (FDA) approved for Parkinson disease and drug-induced dyskinesias,<sup><xref ref-type="bibr" rid="bibr7-0883073812441999">7</xref></sup> as well as for fatigue in multiple sclerosis.<sup><xref ref-type="bibr" rid="bibr8-0883073812441999">8</xref></sup> Additional movement disorders found to improve with amantadine are cerebellar ataxia,<sup><xref ref-type="bibr" rid="bibr9-0883073812441999">9</xref></sup> chorea, as well as akinesia in Huntington disease.<sup><xref ref-type="bibr" rid="bibr10-0883073812441999">10</xref>,<xref ref-type="bibr" rid="bibr11-0883073812441999">11</xref></sup> Its beneficial effect and safety in children was proved in head trauma and attention-deficit disorder.<sup><xref ref-type="bibr" rid="bibr12-0883073812441999">12</xref><xref ref-type="bibr" rid="bibr13-0883073812441999"/><xref ref-type="bibr" rid="bibr14-0883073812441999"/>–<xref ref-type="bibr" rid="bibr15-0883073812441999">15</xref></sup> The mechanism of amantadine is not entirely clear; it was initially considered to inhibit synaptic uptake of dopamine, but probably much of its effect is due to striatal <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptors antagonism.<sup><xref ref-type="bibr" rid="bibr16-0883073812441999">16</xref>,<xref ref-type="bibr" rid="bibr17-0883073812441999">17</xref></sup></p>
<p>The purpose of this study is to investigate whether amantadine improves neurologic symptoms in patients with ataxia telangiectasia while establishing a model for interventional studies in this disease.</p>
<sec id="section1-0883073812441999" sec-type="methods">
<title>Methods</title>
<sec id="section2-0883073812441999">
<title>Population</title>
<p>Patients older than 4 years of age with measurable neurologic disability followed at the National A-T Clinic at the Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, in Israel were recruited. Diagnostic criteria were typical clinical picture plus 1 of the following: (1) a proven mutation in the ATM gene, (2) deficient ATM protein on Western blotting, (3) elevated α-fetoprotein/chromosomal breakage plus immune deficiency and/or history of T-cell malignancy. Patients with major comorbidity (ie, active malignancy, liver or renal failure), sexually active, known to be hypersensitive to amantadine or treated previously with amantadine were excluded.</p>
</sec>
<sec id="section3-0883073812441999">
<title>Study Design</title>
<p>Open label, prospective study; the study was designed for 8 weeks, and consisted of 3 visits. Each visit included quantitative assessment of the neurologic disability according to a battery of validated scales (detailed below). At first visit (baseline), amantadine dosage was gradually titrated up to 5 mg/kg. At the second visit (after 4 weeks), dosage was increased to 7 mg/kg in patients who did not report side effects. In patients reporting significant side effects, dosage was reduced. At the third visit (after 8 weeks), patients were given an option to continue the study drug or to gradually taper down and withdraw the drug.</p>
<p>The neurologic evaluation was performed by a single rater (AN). Three validated scales were used for assessing the main features: cerebellar ataxia, parkinsonism, and involuntary movements. Ataxia was rated using the International Cooperative Ataxia Scale (ICARS)<sup><xref ref-type="bibr" rid="bibr18-0883073812441999">18</xref></sup>; (item 14—drawing of a spiral—was interchanged with writing sample or shape drawing in an age-matched manner). Parkinsonism was scored using the Unified Parkinson Disease Rating Scale (UPDRS) section III (motor items)<sup><xref ref-type="bibr" rid="bibr19-0883073812441999">19</xref></sup>; items 18 (speech), 21 (intention tremor), and 29 (gait) were excluded because they are influenced by cerebellar dysfunction. Hyperkinetic movements (chorea, myoclonus, and dystonia) were rated using the Abnormal Involuntary Movement Scale<sup><xref ref-type="bibr" rid="bibr20-0883073812441999">20</xref></sup> (items 1-9).</p>
<p>Severity of the neurologic disease was quantified using an ad hoc A-T score, composed of the sum of the 3 scales. The highest possible score for worst disease is 156 points: International Cooperative Ataxia Scale 76, Unified Parkinson Disease Rating Scale 44, and Abnormal Involuntary Movement Scale.<sup>36</sup> The relative contribution to the total scale of ataxia was 48.71%, parkinsonism/bradykinesia 28.2%, and involuntary movements 23.02%.</p>
<p>The Clinical Global Impression of Change graded by physicians and parents was used as an additional subjective measure of disease severity. This score encompasses 7 grades, from 1 = significant improvement to 7 = severe deterioration.<sup><xref ref-type="bibr" rid="bibr21-0883073812441999">21</xref></sup></p>
<p>Two additional time-framed tests were used: number of hand taps during 30 seconds and walking 10 m in the hallway. Patients unable of independent walking used the most comfortable support by the accompanying person (the same degree of support was used in all evaluations).</p>
<p><italic>The primary endpoint</italic> was improvement in A-T score. Patients with at least 20% improvement were considered responders. The degree of change was considered mild if there was an improvement of 20% to 39% in the A-T score, moderate for 40% to 59% and excellent for more than 60%. <italic>Secondary endpoints</italic> were improvement in each symptom as measured by the various scales: International Cooperative Ataxia Scale for ataxia, Unified Parkinson Disease Rating Scale for parkinsonism/bradykinesia, Abnormal Involuntary Movement Scale for hyperkinetic movements, the timed motor tasks, and Clinical Global Impression of Change.</p>
</sec>
<sec id="section4-0883073812441999">
<title>Statistical Methods</title>
<p>To assess change between baseline and endpoint, we used paired <italic>t</italic> tests. Influence of additional variables (age, sex, mutation, drug dosage, and severity of disease) on the response (change in scores from baseline to endpoint) was tested by using Pearson correlations and independent <italic>t</italic> tests. All tests applied were 2 tailed, and <italic>P</italic> values of 5% or less were considered statistically significant.</p>
<p>Dropout patients were considered as nonresponders in an intention-to-treat analysis. To prevent bias caused by patients who dropped out because of lack of efficacy, all analyses were done excluding dropout patients and repeated afterward when including their results from the second visit.</p>
<p>The study was approved by the Institutional Regulatory Board no. 1651/1986 (National Institutes of Health trial NCT 00950196). Patients were recruited after they or their parents (for underage children) signed an informed consent in accordance with the Good Clinical Practice guidelines.</p>
</sec>
</sec>
<sec id="section5-0883073812441999">
<title>Results</title>
<sec id="section6-0883073812441999">
<title>Population</title>
<p>Seventeen patients were enrolled in this study, 12 boys and 5 girls. The mean age at enrollment was 11.2 ± 3.9 (range, 4-18 years). Fifteen patients had known mutations in the ATM gene (7430 del 4 in 8 patients, T103C in 3, 3678 delA, 30del 215, C1339 T, and T1514C/T1447C in 1 each). One patient was diagnosed by abnormal chromosomal breakage and 1 by low ATM protein on Western blot. Sixteen patients completed the study; 1 dropped out because of lack of efficacy after the second visit.</p>
</sec>
<sec id="section7-0883073812441999">
<title>Primary Endpoint</title>
<p>In all, 13 of 17 patients (76.5%) were included in the study (<xref ref-type="table" rid="table1-0883073812441999">Table 1</xref>, <xref ref-type="fig" rid="fig1-0883073812441999">Figure 1</xref>). The mean A-T score decreased from 76.47 ± 17.47 at baseline to 54.94 ± 17.83 after 8 weeks (<italic>P</italic> &lt; .01, <italic>t</italic> test, df = 16), an improvement of 29.3% ± 12.77%. The degree of improvement was graded as mild (20%-39%) in 11 patients and moderate (40%-59%) in 2. Worsening of the A-T score was not documented in any patient.</p>
<fig id="fig1-0883073812441999" position="float">
<label>Figure 1.</label>
<caption>
<p>Motor scales at baseline and 8 weeks *<italic>P</italic> &lt; .001, paired <italic>t</italic> test.</p>
</caption>
<graphic alternate-form-of="fig1-0883073812441999" xlink:href="10.1177_0883073812441999-fig1.tif"/>
</fig>
<table-wrap id="table1-0883073812441999" position="float">
<label>Table 1.</label>
<caption>
<p>Results.</p>
</caption>
<graphic alternate-form-of="table1-0883073812441999" xlink:href="10.1177_0883073812441999-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Baseline</th>
<th>8 weeks</th>
<th>Improvement (%)</th>
<th>
<italic>P</italic> (<italic>t</italic> test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-T score</td>
<td>76.7 ± 17.48</td>
<td>54.94 ± 17.83</td>
<td>29.3 ± 12.7</td>
<td>&lt;.01**</td>
</tr>
<tr>
<td>ICARS (ataxia)</td>
<td>38.94 ± 10.13</td>
<td>29.35 ± 10.05</td>
<td>25.2 ± 14.6</td>
<td>&lt;.01**</td>
</tr>
<tr>
<td>AIMS (involuntary movements)</td>
<td>20 ± 4.5</td>
<td>13.65 ± 5.96</td>
<td>32.5 ± 24.1</td>
<td>&lt;.01**</td>
</tr>
<tr>
<td>UPDRS (parkinsonism)</td>
<td>17.53 ± 6.26</td>
<td>11.94 ± 4.48</td>
<td>29.5 ± 17.5</td>
<td>&lt;.01**</td>
</tr>
<tr>
<td>30-sec taps (number)</td>
<td>37.18 ± 16.31</td>
<td>43.41 ± 10.85</td>
<td>27.29 ± 26.4</td>
<td>&gt;.05</td>
</tr>
<tr>
<td>10-m walk (sec)</td>
<td>17.18 ± 7.12</td>
<td>12.46 ± 5.16</td>
<td>34.4 ± 20.5</td>
<td>&lt;.05*</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0883073812441999">
<p>Abbreviations: AIMS, Abnormal Involuntary Movement Scale; ICARS, International Cooperative Ataxia Scale; UPDRS, Unified Parkinson Disease Rating Scale.</p>
</fn>
<fn id="table-fn3-0883073812441999">
<p>*<italic>P</italic> &lt; .05, paired <italic>t</italic> test.</p>
</fn>
<fn id="table-fn4-0883073812441999">
<p>**<italic>P</italic> &lt; .01, paired <italic>t</italic> test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>After completing the study, 9 patients chose to continue chronic treatment with amantadine. Follow-up visits at 6 and 12 months showed no significant change in neurologic score as compared with 8 weeks’ visit (Wilcoxon ranking test). Follow-up visits in 7 patients who discontinued the drug revealed significant neurologic deterioration (Wilcoxon ranking test, <italic>P</italic> &lt; .5). The patient who dropped out was lost to follow-up.</p>
</sec>
<sec id="section8-0883073812441999">
<title>Secondary Endpoints</title>
<p>Ataxia improved significantly as International Cooperative Ataxia Scale decreased from 38.94 ± 10.13 to 29.35 ± 10.05 (<italic>P</italic> &lt; .01, <italic>t</italic> test, df 16) (<xref ref-type="fig" rid="fig1-0883073812441999">Figure 1</xref>, <xref ref-type="table" rid="table1-0883073812441999">Table 1</xref>). The static domain (measuring gait ataxia) and the kinetic domain (measuring tremor and dysmetria) improved equally. Parkinsonism and involuntary movements improved as well: the Unified Parkinson Disease Rating Scale score decreased from 17.53 ± 6.26 to 11.94 ± 4.47 (<italic>P</italic> &lt; .01, <italic>t</italic> test, df = 16) and Abnormal Involuntary Movement Scale score decreased from 20 ± 4.50 to 13.65 ± 5.96 (<italic>P</italic> &lt; .01, <italic>t</italic> test, df = 16). Improvement was similar for ataxia (25.27%), involuntary movements (32.53%), and parkinsonism (29.49%).</p>
<p>Number of taps in 30 seconds increased from 37.2 ± 16.3 to 43.41 ± 10.85, but failed to reach statistical significance. Thirteen patients completed the 10-m walking test; walking time decreased from 17.38 ± 7.12 seconds to 12.24 ± 5.12 (<italic>P</italic> &lt; .05, <italic>t</italic> test, df = 12).</p>
<p>Ataxia was more likely to improve in boys than in girls (<italic>P</italic> &lt; .05, <italic>t</italic> test), but there was no difference in the A-T score. There was a positive correlation between higher drug dosage and improvement in A-T score (Pearson correlation, <italic>P</italic> &lt; .05). Mutation type, patient's age, and ambulation capacity (walking independently) did not influence the improvement. Duration of disease symptoms did not affect the outcome either.</p>
<p>None of the results was influenced by performing an intention-to-treat analysis, that is, by adding the data from the second visit for the patient who dropped out.</p>
<p>Subjective improvement was measured by the Clinical Global Impression of Change score (<xref ref-type="fig" rid="fig2-0883073812441999">Figure 2</xref>): 88.2% (15/17) of the patients improved according to physician's impression and 82.4% (14/17) according to the parent’s impression. Degree of improvement was rated as mostly mild to moderate. Parents mentioned ataxia followed by manual skills and hyperkinetic movements as the most improved symptoms. Other symptoms reported by parents to be improved (not accurately measured by the existent scales) were eye movements, communication skills, and hypersalivation.</p>
<fig id="fig2-0883073812441999" position="float">
<label>Figure 2.</label>
<caption>
<p>Clinical global impression of change according to investigator and parent.</p>
</caption>
<graphic alternate-form-of="fig2-0883073812441999" xlink:href="10.1177_0883073812441999-fig2.tif"/>
</fig>
</sec>
<sec id="section9-0883073812441999">
<title>Amantadine Dosage</title>
<p>The mean dosage used at the end of 8 weeks was 6.3 mg/kg. At 4 weeks, 12 patients increased the dosage from 5 mg/kg up to 7 mg/kg; the increased dosage improved the clinical score in 5 patients, remained unchanged in 5, and worsened the clinical outcome in 2. One patient decreased the dose after 4 weeks because of side effects.</p>
</sec>
<sec id="section10-0883073812441999">
<title>Side Effects</title>
<p>Side effects were abdominal pain (6 patients), nausea (2), constipation (1), sleepiness (1), headache (1), and rash (1). In all patients, discomfort was mild to moderate and none dropped out of the study because of side effects.</p>
</sec>
</sec>
<sec id="section11-0883073812441999">
<title>Discussion</title>
<p>Since the discovery in 1995 of the genetic defect in ataxia telangiectasia,<sup><xref ref-type="bibr" rid="bibr22-0883073812441999">22</xref></sup> most efforts concentrate on the role of the ATM protein as a central protein in DNA repair. In neuronal cells, unrepaired DNA tend to accumulate and eventually cause the death of Purkinje cells by a common final pathway shared with several neurodegenerative disorders. Oxidative processes, induced by release of oxygen radicals from the mitochondria, is a major contributor to neurodegeneration. Patients with ataxia telangiectasia are especially prone to oxidative stress, because the ATM protein by itself is a scavenger of reactive oxygen species.<sup><xref ref-type="bibr" rid="bibr23-0883073812441999">23</xref></sup>
</p>
<p>However, ataxia appears years before cerebellar atrophy is perceived, suggesting additional mechanisms. Synchronization of the Purkinje cell network and the cells’ fast oscillation causes ataxia.<sup><xref ref-type="bibr" rid="bibr24-0883073812441999">24</xref></sup> Pharmacologic treatment of ataxia is rarely documented, but 1 strategy would be manipulation of the calcium signaling on this network by NMDA receptor agonists.<sup><xref ref-type="bibr" rid="bibr24-0883073812441999">24</xref>,<xref ref-type="bibr" rid="bibr25-0883073812441999">25</xref></sup>
</p>
<p>Basal ganglia symptomatology in ataxia telangiectasia as chorea, dystonia, and bradykinesia is even more intriguing, because imaging of basal ganglia is normal. Dysregulation of dopamine in the nigrostriatal circuitry was found in spinocerebellar ataxias<sup><xref ref-type="bibr" rid="bibr26-0883073812441999">26</xref>,<xref ref-type="bibr" rid="bibr27-0883073812441999">27</xref></sup> as well as ataxia-oculomotor apraxia 1 (another ataxia caused by a defect in DNA repair).<sup><xref ref-type="bibr" rid="bibr28-0883073812441999">28</xref></sup> Drugs that increase dopamine in the striatum treat bradykinesia and parkinsonism but exacerbate chorea, and vice versa.</p>
<p>Research on treatment of movement disorders in ataxia telangiectasia is scarce, and most reports are anecdotal.<sup><xref ref-type="bibr" rid="bibr1-0883073812441999">1</xref>,<xref ref-type="bibr" rid="bibr2-0883073812441999">2</xref></sup> Studies by Broccoletti et al<sup><xref ref-type="bibr" rid="bibr4-0883073812441999">4</xref>,<xref ref-type="bibr" rid="bibr5-0883073812441999">5</xref></sup> on the role of betamethasone are the only interventional studies published to date. The mechanism of action of steroids is probably by their antioxidative effect.<sup><xref ref-type="bibr" rid="bibr6-0883073812441999">6</xref></sup>
</p>
<p>In this study, using a simple model for measuring disease severity, we found that the dopaminergic and anti-NMDA agent amantadine sulfate improves the neurologic symptoms in ataxia telangiectasia. Seventy-five percent of patients were responders, showing more than 20% improvement on the general neurologic score (A-T score); the drug affected to the same degree cerebellar (ataxia) as well as extrapyramidal (parkinsonism, hyperkinesia) symptoms without exacerbating movement disorder. There was no influence of phenotype (mutation, age, severity of disease) on the magnitude of the response. The drug was well tolerated at a dosage from 5 to 7 mg/kg; increasing the dosage from 5 to 7 mg/kg increased the positive response.</p>
<p>The effect of amantadine on various aspects of movement disorder in ataxia telangiectasia is explained by its dual action. It increases dopamine in the synaptic cleft by inhibition of reuptake and by facilitating direct release.<sup><xref ref-type="bibr" rid="bibr16-0883073812441999">16</xref></sup> Therefore, the improvement in bradykinesia that we documented is probably explained by a dopaminergic mechanism well known for more than 40 years.<sup><xref ref-type="bibr" rid="bibr29-0883073812441999">29</xref></sup> Interestingly, amantadine did not deteriorate chorea and other hyperkinetic movements as dopaminergic drugs do, but significantly improved them. Amantadine was previously reported to be beneficial in chorea (Huntington chorea)<sup><xref ref-type="bibr" rid="bibr10-0883073812441999">10</xref></sup>; the speculated mechanism is via blocking of striatal glutamatergic system,<sup><xref ref-type="bibr" rid="bibr10-0883073812441999">10</xref></sup> which is involved in pathogenesis of chorea.<sup><xref ref-type="bibr" rid="bibr30-0883073812441999">30</xref></sup>
</p>
<p>Glutamate is the major excitatory neurotransmitter. It binds to the NMDA receptors, which are widespread in the brain (cerebellum, hippocampus, and striatum), and causes opening of calcium channels.<sup><xref ref-type="bibr" rid="bibr31-0883073812441999">31</xref></sup> Short opening of the calcium channel is essential in physiologic activity. Pathologic activation due to prolonged opening exaggerates calcium efflux, resulting in rapid oscillation of Purkinje cells,<sup><xref ref-type="bibr" rid="bibr24-0883073812441999">24</xref>,<xref ref-type="bibr" rid="bibr25-0883073812441999">25</xref>,<xref ref-type="bibr" rid="bibr32-0883073812441999">32</xref></sup> and in the long run will cause cell death and neurodegeneration.<sup><xref ref-type="bibr" rid="bibr31-0883073812441999">31</xref></sup>
</p>
<p>Amantadine inhibits NMDA receptors, accelerates channel closure, and decreases calcium efflux.<sup><xref ref-type="bibr" rid="bibr16-0883073812441999">16</xref>,<xref ref-type="bibr" rid="bibr17-0883073812441999">17</xref></sup> Because it binds preferentially to pathologically activated NMDA channel, it is exceptionally well tolerated.<sup><xref ref-type="bibr" rid="bibr31-0883073812441999">31</xref></sup> This newly recognized mechanism of action<sup><xref ref-type="bibr" rid="bibr24-0883073812441999">24</xref></sup> explains the positive effect on ataxia that had been described previously in adults<sup><xref ref-type="bibr" rid="bibr9-0883073812441999">9</xref>,<xref ref-type="bibr" rid="bibr33-0883073812441999">33</xref></sup> In addition to positively affecting ataxia, the NMDA antagonism of amantadine explains its positive influence on chorea.<sup><xref ref-type="bibr" rid="bibr10-0883073812441999">10</xref>,<xref ref-type="bibr" rid="bibr30-0883073812441999">30</xref></sup>
</p>
<p>Our study was designed for a short-term intervention; therefore, only the immediate effect on neurotransmitter imbalance is expected. Newer NMDA antagonists are extensively explored nowadays for their putative effect on preventing cell death and neurodegeneration.<sup><xref ref-type="bibr" rid="bibr31-0883073812441999">31</xref></sup> Further studies on the role of amantadine, or the more potent NMDA receptor agonist memantine,<sup><xref ref-type="bibr" rid="bibr31-0883073812441999">31</xref></sup> on degeneration of Purkinje cells in ataxia telangiectasia are warranted.</p>
<p>Conducting clinical studies in patients with ataxia telangiectasia requires a quantitative measurement of ataxia as well as extrapyramidal movement disorder, fatigue, eye movements, dysarthria, and impaired communication. Crawford et al<sup><xref ref-type="bibr" rid="bibr34-0883073812441999">34</xref></sup> made the first attempt to build such a scale, but this scale is underused because it is impractical and lacks some of the symptoms (as bradykinesia). An International Committee is working on a neurologic scale dedicated to ataxia telangiectasia based on Crawford’s scale, which should encompass the wide variety of neurologic symptoms (personal communication). Meanwhile, interventional studies are not done or check only ataxia .<sup><xref ref-type="bibr" rid="bibr4-0883073812441999">4</xref><xref ref-type="bibr" rid="bibr5-0883073812441999"/><xref ref-type="bibr" rid="bibr6-0883073812441999"/>–<xref ref-type="bibr" rid="bibr7-0883073812441999">7</xref></sup></p>
<p>In this study, we created a paradigm for scoring neurologic symptoms suited for interventional studies, using various validated scales. For this purpose, we concentrated on 3 major manifestations of ataxia-telangiectasia: ataxia using the International Cooperative Ataxia Scale, hyperkinetic movements using the Abnormal Involuntary Movement Scale, and parkinsonism/bradykinesia using the Unified Parkinson Disease Rating Scale. The A-T score we created is weighted in such a manner that half of the points derive from ataxia and cerebellar symptoms, and the other half divides between the extrapyramidal symptoms. This distribution suits the contributions of various symptoms to the morbidity of the patients; however, in our score, eye movement (based on the International Cooperative Ataxia Scale) is underrepresented. An additional limitation is the inability to accurately measure fatigue by the 2 time framed tests, 30-second hand taps and 10 meter walk, because they are also influenced by ataxia, dyspraxia, and bradykinesia.</p>
<p>Another drawback of our study, dictated by budget constraints, is lack of placebo control. Long-term, placebo-controlled studies on the effect of NMDA antagonists (amantadine, memantine) on movement disorder and general neurologic course in ataxia telangiectasia should follow. Early treatment in asymptomatic children could be speculated to delay cerebellar degeneration.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1a-0883073812441999"><label>Author Contributions</label>
<p>AN and SHB designed the study, with contributions from YBL and BBZ. AN and YBL collected the data, along with MT. AN and SFL analyzed the data. AN wrote the first draft, with contributions from all other authors. AN along with BBZ wrote the final manuscript and all other authors approved it. No honorarium or any kind of payment was offered for ghost writers.</p></fn>
<fn fn-type="conflict" id="fn1-0883073812441999"><label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. </p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0883073812441999"><label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article. </p>
</fn>
<fn fn-type="other" id="fn2a-0883073812441999"><label>Ethical Approval</label>
<p>The study was approved by the Institutional Regulatory Board No. 1651/1986 (NIH trial NCT 00950196). Patients were recruited after they or their parents (for underage children) signed an informed consent in accordance with the Good Clinical Practice guidelines.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812441999">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gueven</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bottle</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gatti</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia</article-title>. <source>Br Med Bull</source>. <year>2007</year>;<volume>81</volume>:<fpage>129</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr2-0883073812441999">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Becker-Catania</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gatti</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Ataxia-telangiectasia: diagnosis and treatment</article-title>. <source>Semin Pediatr Neurol</source>. <year>2003</year>;<volume>3</volume>:<fpage>173</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812441999">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nissenkorn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Levi</surname>
<given-names>YB</given-names>
</name>
<name>
<surname>Vilozni</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group> <article-title>Neurologic presentation in ataxia-telangiectasia—is small head circumference a hallmark of disease</article-title>. <source>J Pediatr</source>. <year>2011</year>;<volume>159</volume>:<fpage>466.e1</fpage>–<lpage>471.e1</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812441999">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broccoletti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Del</surname>
<given-names>Giudice E</given-names>
</name>
<name>
<surname>Amorosi</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients</article-title>. <source>Eur J Neurol</source>. <year>2008</year>;<volume>15</volume>:<fpage>223</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812441999">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broccoletti</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Del</surname>
<given-names>Giudice E</given-names>
</name>
<name>
<surname>Cirillo</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group> <article-title>Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia</article-title>. <source>Eur J Neurol</source>. <year>2011</year>;<volume>18</volume>:<fpage>564</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812441999">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Del</surname>
<given-names>Giudice E</given-names>
</name>
<etal/>
</person-group> <article-title>In ataxia-telangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity</article-title>. <source>Eur J Neurol</source>. <year>2009</year>;<volume>16</volume>:<fpage>755</fpage>–<lpage>759</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812441999">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luginger</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wenning</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Bosch</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Beneficial effects of amantadine on <sc>l</sc>-DOPA induced dyskinesia in Parkinson disease</article-title>. <source>Mov Dis</source>. <year>2000</year>;<volume>15</volume>:<fpage>873</fpage>–<lpage>878</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812441999">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krupp</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Doscher</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo</article-title>. <source>Neurology</source>. <year>1995</year>;<volume>45</volume>:<fpage>1956</fpage>–<lpage>1961</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812441999">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Botez</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Botez-Marquard</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Elie</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Amantadine hydrochloride treatment in heredo-degenerative ataxias: a double blind study</article-title>. <source>J Neurol Neurosurg Psychiatry</source>. <year>1996</year>;<volume>61</volume>:<fpage>259</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812441999">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verhagen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine</article-title>. <source>Neurology</source>. <year>2002</year>;<volume>59</volume>:<fpage>694</fpage>–<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr11-0883073812441999">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magnet</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Bonelly</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hapfhammer</surname>
<given-names>HP</given-names>
</name>
</person-group>. <article-title>Amantadine in akinetic-rigid variant of Huntington's disease</article-title>. <source>Ann Pharmacother</source>. <year>2004</year>;<volume>38</volume>:<fpage>1194</fpage>–<lpage>1196</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812441999">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glezen</surname>
<given-names>WP</given-names>
</name>
</person-group>. <article-title>Indications for amantadine in otherwise healthy children</article-title>. <source>Pediatr Inf Dis J</source>. <year>1993</year>;<volume>12</volume>:<fpage>106</fpage>.</citation>
</ref>
<ref id="bibr13-0883073812441999">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patrick</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Blackman</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Mabry</surname>
<given-names>JL</given-names>
</name>
<etal/>
</person-group> <article-title>Dopamine agonists therapy in low-response children following traumatic brain injury</article-title>. <source>J Child Neurol</source>. <year>2006</year>;<volume>21</volume>:<fpage>879</fpage>–<lpage>885</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812441999">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meythaler</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Novack</surname>
<given-names>TA</given-names>
</name>
</person-group>. <article-title>Amantadine to improve neurorecovery in traumatic brain injury: a pilot double-blind randomized trial</article-title>. <source>J Head Trauma Rehabil</source>. <year>2002</year>;<volume>17</volume>:<fpage>300</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812441999">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donafrancesco</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Calderoni</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vitiello</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Open-label amantadine in children with attention deficit/hyperactivity disorder</article-title>. <source>J Child Neurol Adolesc Psychopharmacol</source>. <year>2007</year>;<volume>17</volume>:<fpage>657</fpage>–<lpage>663</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812441999">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizoguchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yokoo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by <italic>N</italic>-methyl-<sc>d</sc>-aspartate antagonism</article-title>. <source>Brain Res</source>. <year>1994</year>;<volume>662</volume>:<fpage>255</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812441999">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanpied</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Amantadine inhibits NMDA receptors by accelerating channel closure during channel block</article-title>. <source>J Neurosci</source>. <year>2005</year>;<volume>25</volume>:<fpage>3312</fpage>–<lpage>3322</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812441999">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trouillars</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Takayanagi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hallet</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome</article-title>. <source>J Neurol Sci</source>. <year>1997</year>;<volume>145</volume>:<fpage>205</fpage>–<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812441999">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Martin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gil-Najel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gracia</surname>
<given-names>LM</given-names>
</name>
<etal/>
</person-group> <article-title>Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group</article-title>. <source>Mov Disord</source>. <year>1994</year>;<volume>9</volume>:<fpage>76</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr20-0883073812441999">
<label>20</label>
<citation citation-type="journal">
<collab collab-type="author">Abnormal Involuntary Movement Scale (AIMS)</collab>. <source>Psychopharmacol Bull</source>. <year>1988</year>;<volume>24</volume>:<fpage>781</fpage>–<lpage>783</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812441999">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schneider</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Olin</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Doody</surname>
<given-names>RS</given-names>
</name>
<etal/>
</person-group> <article-title>Validity and reliability of the Alzheimer's Disease Cooperative Study: clinical global impression of change</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>1997</year>;<volume>11</volume>:<fpage>S22</fpage>–<lpage>S31</lpage>.</citation>
</ref>
<ref id="bibr22-0883073812441999">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savitsky</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bar-Shira</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gilad</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>A single ataxia telangiectasia gene with a product similar to PI-3 kinase</article-title>. <source>Science</source>. <year>1995</year>;<volume>268</volume>:<fpage>1749</fpage>–<lpage>1753</lpage>.</citation>
</ref>
<ref id="bibr23-0883073812441999">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kozlov</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lavin</surname>
<given-names>MF</given-names>
</name>
<etal/>
</person-group> <article-title>ATM activation by oxidative stress</article-title>. <source>Science</source>. <year>2010</year>;<volume>330</volume>:<fpage>517</fpage>–<lpage>521</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812441999">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheron</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Servais</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Dan</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Cerebellar network plasticity: from genes to fast oscillation</article-title>. <source>Neuroscience</source>. <year>2008</year>;<volume>153</volume>:<fpage>1</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812441999">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Pharmacological treatments of cerebellar ataxia</article-title>. <source>Cerebellum</source>. <year>2004</year>;<volume>3</volume>:<fpage>107</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812441999">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cubo</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Ceberio</surname>
<given-names>JI</given-names>
</name>
<etal/>
</person-group> <article-title>Striatal dopamine function in a family with multiple SCA-3 phenotypes</article-title>. <source>J Neurol</source>. <year>2011</year>;<volume>258</volume>:<fpage>308</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812441999">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hearst</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Q</given-names>
</name>
<etal/>
</person-group> <article-title>Dopamine D2 receptor signaling modulates mutant ataxin-1 S776 phosphorylation and aggregation</article-title>. <source>J Neurochem</source>. <year>2010</year>;<volume>114</volume>:<fpage>706</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812441999">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salvatore</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Varrone</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Crisculo</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Nigrostriatal involvement in ataxia with oculomotor apraxia type1</article-title>. <source>J Neurol</source>. <year>2008</year>;<volume>255</volume>:<fpage>45</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812441999">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grelak</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stump</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Vernier</surname>
<given-names>VG</given-names>
</name>
</person-group>. <article-title>Amantadine-dopamine interaction: possible mode of action in parkinsonism</article-title>. <source>Science</source>. <year>1970</year>;<volume>169</volume>:<fpage>203</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr30-0883073812441999">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yakimovskii</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Varshavskaya</surname>
<given-names>VM</given-names>
</name>
</person-group>. <article-title>Neostriatal glutamatergic system is involved in the pathogenesis of picrotoxin induced choreomyoclonic hyperkinesis</article-title>. <source>Bull Exp Biol Med</source>. <year>2004</year>;<volume>138</volume>:<fpage>533</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr31-0883073812441999">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipton</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond</article-title>. <source>Nat Rev</source>. <year>2006</year>;<volume>5</volume>:<fpage>160</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr32-0883073812441999">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogawa</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Shigeto</surname>
<given-names>H</given-names>
</name>
</person-group>, <article-title>Yamamto T, et al. <sc>d</sc>-Cycloserine for the treatment of ataxia in spinocerebellar degeneration</article-title>. <source>J Neurol Sci</source>. <year>2003</year>;<volume>210</volume>;<fpage>53</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr33-0883073812441999">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassin-Baer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Korczyn</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Giladi</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment</article-title>. <source>J Neural Transm</source>. <year>2000</year>;<volume>107</volume>:<fpage>1187</fpage>–<lpage>1189</lpage>.</citation>
</ref>
<ref id="bibr34-0883073812441999">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname>
<given-names>TO</given-names>
</name>
<name>
<surname>Mandir</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Lefton-Greif</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group> <article-title>Quantitative neurologic assessment of ataxia-telangiectasia</article-title>. <source>Neurology</source>. <year>2000</year>;<volume>54</volume>:<fpage>1505</fpage>–<lpage>1509</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>